NVX-Cov2373

Drug identity checked against registry records

Also recorded as SARS-CoV-2 rS/Matrix-M Adjuvant

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant VaccinesNCT05372588NovavaxPhase 3Completed2022-07-17Actual
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in AdultsNCT05463068NovavaxPhase 3Completed2022-08-17Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.